Discovery process and characterization of novel carbohydrazide derivatives as potent and selective GHSR1a antagonists

ChemMedChem

Volumn 5, Issue 9, 2010, Pages 1450-1455

  Sabbatini, Fabio Maria ^a   Di Fabio, Romano ^a   Corsi, Mauro ^a   Cavanni, Paolo ^a   Bromidge, Steve M ^a,b   St Denis, Yves ^a   D'Adamo, Lucilla ^a,c   Contini, Stefania ^a   Rinaldi, Marilisa ^a   Guery, Sebastien ^a   Savoia, Chiara ^a   Mundi, Claudia ^a   Perini, Benedetta ^a   Carpenter, Andrew J ^a,c   Forno, Giovanna Dal ^a   Faggioni, Federico ^a   Tessari, Michela ^a   Pavone, Francesca ^a   Francesco, Carla Di ^a   Buson, Alberto ^a   Mattioli, Mario ^a   Perdona', Elisabetta ^a   Melotto, Sergio ^a,c   DemangeL, R J ^a,b,c   Mousseaux, D ^a,b,c   Sanchez, P ^a,b,c   Berge, G ^a,b,c   Gagne, D ^a,b,c   Perrissoud, D ^a,b,c   Locatelli, V ^a,b,c   Torsello, A ^a,b,c   Galleyrand, J C ^a,b,c   Fehrentz, J A ^a,b,c   Martinez, J ^a,b,c   more..

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Antagonists; Eating disorders; Ghrelin; GHSR1a

Indexed keywords

GHRELIN RECEPTOR BLOCKING AGENT; GROWTH HORMONE; HORMONE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; GROWTH HORMONE RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION;

CELL LINE; DRUG EVALUATION, PRECLINICAL; EATING DISORDERS; HUMANS; HYDRAZINES; RECEPTORS, GHRELIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77956402546     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201000185     Document Type: Article

References (22)

1. S. Gnanapavan, B. Kola, S. A. Bustin, D. G. Morris, P. McGee, P. Fairclough, S. Bhattacharya, R. Carpenter, A. B. Grossman, M. J. Korbonits, Clin. Endocrinol. Metab. 2002, 87, 2988.
2. W. A. Banks, M. Tschop, S. M. Robinson, M. L. Heiman, J. Pharmacol. Exp. Ther. 2002, 302, 822-827.
3. A. M. Wren, L. J. Seal, M. A. Cohen, A. E. Brynes, G. S. Frost, K. G. Murphy, W. S. Dhillo, M. A. Ghatei, S. R. Bloom, J. Clin. Endocrinol. Metab. 2001, 86, 5992.
4. M. Korbonits, A. P. Goldstone, M. Gueorguiev, A. B. Grossman, Front. Neuroendocrinol. 2004, 25, 27-68.
5. A. F. Leite-Moreira, J. B. Soares, Drug Discovery Today 2007, 12, 276-288.
6. D. E. Cummings, Physiol. Behav. 2006, 89, 71-84.
7. H. Schellekens, T. G. Dinan, J. F. Cryan, Neuropharmacology 2010, 58, 2-16.
8. G. Muccioli, M. Tschöp, M. Papotti, R. Deghenghi, M. Heiman, E. Ghigo, Eur. J. Pharmacol. 2002, 440, 235.
9. F. I. Cordido, R. Nemina, S. Sangiao-Alvarellos, Curr. Drug Discovery Technol. 2009, 6, 34-42.
10. G. Muccioli, A. Baragli, R. Granata, M. Papotti, E. Ghigo, Neuroendocrinology 2007, 86, 147-164.
11. P. A. Carpino, G. Ho, Expert Opin. Ther. Pat. 2008, 18, 1253-1263.
12. B. Liu, M. Liu, Z. Xin, H. Zhao, M. D. Serby, C. Kosogof, L. T. Nelson, B. G. Szczepankiewicz, W. Kaszubska, V. G. Schaefer, H. D. Falls, C. W. Lin, C. A. Collins, H. L. Sham, G. Liu, Bioorg. Med. Chem. Lett. 2006, 16, 1864-1868.
13. J. Rudolph, W. P. Esler, S. O'Connor, P. D. Coish, P. L. Wickens, M. Brands, D. E. Bierer, B. T. Bloomquist, G. Bondar, L. Chen, C. Y. Chuang, T. H. Claus, Z. Fathi, W. Fu, U. R. Khire, J. A. Kristie, X. G. Liu, D. B. Lowe, A. C. McClure, M. Michels, A. A. Ortiz, P. D. Ramsden, R. W. Schoenleber, T. E. Shelekhin, A. Vakalopoulos, W. Tang, L. Wang, L. Yi, S. J. Gardell, J. N. Livingston, L. J. Sweet, W. H. Bullock, J. Med. Chem. 2007, 50, 5202-5216.
14. A. Moulin, R. J. DemangeL, D. Mousseaux, P. Sanchez, G. Berge, D. Gagne, D. Perrissoud, V. Locatelli, A. Torsello, J. C. Galleyrand, J. A. Fehrentz, J. Martinez, J. Med. Chem. 2008, 51, 689-693.
15. A. Pasternak, D. Goble, S.; R. K. deJesus, D. L. Hreniuk, C. Chung, M. Tota, P. Mazur, S. D. Feighner, Andrew, D. Howard, S. G. Mills, L. Yang, Bioorg. Med. Chem. Lett. 2009, 19, 6237-6240;
16. R. K. deJesus, D. L. Hreniuk, C. Chung, M. Tota, P. Mazur, S. D. Feighner, Andrew, D. Howard, S. G. Mills, L. Yang, Bioorg. Med. Chem. Lett. 2009, 19, 6237-6240.
17. S. K. Davidsen, P. D. May, J. B. Summers, J. Org. Chem. 1991, 56, 5482-5485.
18. G. Alvaro, D. Andreotti, S. Belvedere, R. Di Fabio, A. Falchi, R. Giovannini, (SmithKline Beecham Co., Philadelphia, USA), WO/2007/028654A1, 2007.
19. N. G. Anderson, Org. Process Res. Dev. 2005, 9, 800-813.
20. Biology and pharmacokinetics: All experiments involving animals were carried out in accordance with European directive 86/609/EEC governing animal welfare and protection, which is acknowledged by Italian Legislative Decree no. 116 (January 27, 1992). Furthermore, experiments were conducted with internal review performed by the GlaxoSmithKline Committee on Animal Research & Ethics (CARE) and in accordance with the company policy on the care and use of laboratory animals.
21. H. Zhao, Drug Discovery Today 2007, 12, 149-155.
22. B. Holst, J. Mokrosinski, M. Lang, E. Brandt, R. Nygaard, Frimurer, M. Thomas, A. G. Beck-Sickinger, T. W. Schwartz, J. Biol. Chem. 2007, 282, 15799-15811.